Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody (R)-PD-L1X4-1BB (GEN1046) trial

Background DuoBody-PD-L1×4-1BB (GEN1046) is a classdefining, bispecific immunotherapy designed to induce an antitumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation. Encouraging clinical activity and manageable safety were observed during dose esca...

Descripción completa

Detalles Bibliográficos
Autores: Ponce, S. (Santiago)|||/items/523cce19-eb1c-410f-b829-8dbc7466c765, Calvo, E. (Emiliano)|||/items/52242792-ef7e-42a3-80b0-88885264e12c, Moreno-Jiménez, V. (Víctor)|||/items/888d01af-1f4b-4d44-862b-c4539a4ee374, Garralda, E. (Elena)|||/items/86a6b282-a0e6-4c91-9ad6-2689352ec877, Cervantes, A. (Andrés)|||/items/2d6014f5-def2-427b-a305-e97cce2b0aaa, Ramalingam, S. (Suresh)|||/items/a8beaf78-a1fb-418d-a34b-db310f2feb6b, Trigo, J.M. (Jose Manuel)|||/items/7ad3405a-60a2-49db-a622-b79c09852754, LoRusso, P. (Patricia)|||/items/ae4a0545-7775-4897-9aaa-9dcce8a15c47, Furqan, M. (Muhammad)|||/items/9a38a46d-0b13-42b9-94c0-73c50fee5901, Cho, D. (Daniel)|||/items/1b7136f0-5c06-4bf7-9c63-612be2856acc, Muik, A. (Alexander)|||/items/0428e806-c116-4ba4-9485-1790e54c65dd, Lagkadinou, E. (Eleni)|||/items/2f605643-73d7-4708-ba9d-47c3338a480c, Türeci, Ö. (Özlem)|||/items/8302965e-97fb-4300-89ed-a07adb552a1c, Couto, S. (Suzana)|||/items/ba81d2bc-c4ac-4edb-b31d-2b0ea28013d9, Pencheva, N. (Nora)|||/items/9e489a8d-3528-4d7c-b73a-3f5d7a2c0001, Forssmann, U. (Ulf)|||/items/f4159c94-c50f-4611-ae93-d19547ebca81, Sahin, U. (Ugur)|||/items/790b2f07-d07a-40fd-b3ec-1ef328b21694, Ahmad, T. (Tahamtan)|||/items/60bd7843-4ac4-4c55-9564-e8f91c7f7ec1, Higgs, B. (Brandon)|||/items/ed961745-d434-4c99-99a5-4c96e7f2200b, Jure-Kunkel, M. (María)|||/items/27a53a4f-a100-45e9-9312-7aa938524fda, Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/115294
Acceso en línea:https://hdl.handle.net/10171/115294
Access Level:acceso abierto
Palabra clave:DuoBody-PD-L1×4-1BB (GEN1046)
Immunotherapy
Antitumor
PD-L1 blockade
Descripción
Sumario:Background DuoBody-PD-L1×4-1BB (GEN1046) is a classdefining, bispecific immunotherapy designed to induce an antitumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation. Encouraging clinical activity and manageable safety were observed during dose escalation in the ongoing phase 1/2a trial in patients with advanced solid tumors (NCT03917381). We report exploratory pharmacodynamic analyses and potential biomarkers of response in an expansion cohort of patients with PD-(L)1–R/R NSCLC.

Similares en LA Referencia